MedicaNatumin develops, manufactures and markets healthcare products based on innovative ingredients and solid scientific research. The Groups’ patented platforms are developed by our research group in collaboration with the Karolinska and Sahlgrenska institutes. MedicaNatinum’s leading brands within dietary supplements, medical devices, and derma cosmetics are largely sold on the Nordic market, but also to consumers around the world. Additionally, we have distribution rights for a number of popular organic foods and skincare products in the Norwegian market.

The foundation of MedicaNatumin’s business is to offer innovative products and strong brands from a sustainable and scientific base.
Our starting point is to have a strong position on the Nordic market while developing international partnerships and export operations.

We have all essential parts of the organisation; innovation and product development based on a strong patent platform, a local production that meets strict hygiene and quality requirements, a well-functioning sales and marketing department, and the entire organization is penetrated by clear roles and responsibilities.

Shares

Aktiestruktur

Antal aktier	375 989 277
Summa emitterat	375 989 277
Antal aktieägare	1 758 st
Antal teckningsoptioner	16 300 000 (1 option = 1 aktie)
ISIN	Aktie SE0001789793

Aktieägare

Aktieägare	Antal aktier	Andel (ca)
N.P.H i Habo AB	75 000 000	19,95%
Försäkringsbolaget, Avanza Pension	38 339 939	10,20%
Swedbank Försäkring AB	38 018 451	10,11%
TJ Gruppen AB	18 660 142	4,96%
Jool Invest AB	17 448 434	4,64%
Lars-Olof Johansson	8 837 360	2,35%
Jesper Pettersson	8 760 000	2,33%
Jörgen Wehmonen	6 720 660	1,79%
Karl-Olov Eriksson	6 119 725	1,63%
Nordnet Pensionsförsäkring AB	4 920 277	1,31%
Summa	222 824 988	59,26%
Övriga 1 748 aktieägare	153 164 289	40,74%
Totalt antal aktier	375 989 277	100,00 %